As more consumers adjust their eating habits due to the appetite-suppressing effects of GLP-1 medications, food manufacturers are rethinking portion sizes, nutritional profiles, and product formulation strategies
One in eight adults have reported taking a GLP-1 medication, either for chronic health conditions such as type 2 diabetes or for weight loss, according to a May 2024 KKF poll
Numerous smaller supplement brands have entered the market with their own formulations
Im pretty sure all obesity clinicians worldwide are individualising dose according to appetite suppressant, weight loss and side effects
Many adults discover that stubborn weight and persistent cravings resist even the most disciplined efforts
In terms of body weight, oral-semaglutide treatment led to mean reductions of -2.5 kg (treatment-policy estimand) and -2.7 kg (trial-product estimand)